<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03197090</url>
  </required_header>
  <id_info>
    <org_study_id>DETECT-AF Trial</org_study_id>
    <nct_id>NCT03197090</nct_id>
  </id_info>
  <brief_title>Detection of Atrial Fibrillation in the Hospital Setting by Use of a Handheld ECG Recording Device</brief_title>
  <official_title>Detection of Atrial Fibrillation in the Hospital Setting by Use of a Handheld ECG Recording Device - The DETECT-AF Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stéphane Cook, Prof</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Freiburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, open label, randomized control trial to assess the efficacy of a
      one-lead ECG handheld device (Zenicor) for the detection of previously unknown atrial
      fibrillation (AF) in hospitalized patients.

      All patients admitted to the internal medicine department of the Hospital Fribourg throughout
      the study period will be screened for study enrollment. Patients with known or previously
      documented atrial fibrillation, patients with a cardiac pacemaker, and implantable
      cardioverter-defibrillator or intra-cardiac monitoring device will be excluded from the
      present trial. The study population will consist of approximately 800 patients in each group
      at the University of Fribourg Medical Center. Patients must meet all eligibility criteria for
      inclusion into the study.

      Patients allocated to the treatment group will undergo twice daily monitoring with the
      handheld Zenicor ECG. Additional recordings will be obtained whenever patients notice
      palpitations. Recordings will be obtained in the presence of specially trained nurses. The
      recordings will then be validated through a web-based interface offered by Zenicor. The
      one-lead ECGs will be reviewed by the investigating physicians through the Web-based analysis
      service (Zenicor-ECG Doctor System) to assess the presence of atrial fibrillation.

      The primary end point of the study is the percentage of newly detected atrial fibrillation at
      6 months
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2017</start_date>
  <completion_date type="Anticipated">May 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Newly detected atrial fibrillation.</measure>
    <time_frame>For 6 months</time_frame>
    <description>Proportion of newly detected atrial fibrillation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ischaemic stroke</measure>
    <time_frame>1, 2 and 5 years after the index event</time_frame>
    <description>Incidence of ischaemic stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic embolism</measure>
    <time_frame>1, 2 and 5 years after the index event</time_frame>
    <description>Incidence of systemic embolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction.</measure>
    <time_frame>1, 2 and 5 years after the index event</time_frame>
    <description>Incidence of myocardial infarction.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Zenicor ON</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients allocated to the experimental group will undergo systematic short ECG monitoring</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zenicor OFF</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>In patients allocated to the control group, usual diagnostic procedures for detection of atrial fibrillation will be employed according to ESC Guidlines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Zenicor ECG</intervention_name>
    <description>Participants will place their thumbs on the device twice daily and whenever they notice palpitations.</description>
    <arm_group_label>Zenicor ON</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients admitted to the internal medicine department of the University and
             Hospital Fribourg throughout the study period will be screened for study enrollment.

        Exclusion Criteria:

          -  Patients with known or previously documented atrial fibrillation, patients with a
             cardiac pacemaker, and implantable cardioverter-defibrillator or intra-cardiac
             monitoring device will be excluded from the present trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stéphane P Cook, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Freiburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stéphane P Cook, MD</last_name>
    <phone>+41264268140</phone>
    <email>stephanecook@me.com</email>
  </overall_contact>
  <reference>
    <citation>Svennberg E, Engdahl J, Al-Khalili F, Friberg L, Frykman V, Rosenqvist M. Mass Screening for Untreated Atrial Fibrillation: The STROKESTOP Study. Circulation. 2015 Jun 23;131(25):2176-84. doi: 10.1161/CIRCULATIONAHA.114.014343. Epub 2015 Apr 24.</citation>
    <PMID>25910800</PMID>
  </reference>
  <reference>
    <citation>Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012 Nov;33(21):2719-47. doi: 10.1093/eurheartj/ehs253. Epub 2012 Aug 24. Erratum in: Eur Heart J. 2013 Mar;34(10):790. Eur Heart J. 2013 Sep;34(36):2850-1.</citation>
    <PMID>22922413</PMID>
  </reference>
  <reference>
    <citation>Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, Fain E, Yang S, Bailleul C, Morillo CA, Carlson M, Themeles E, Kaufman ES, Hohnloser SH; ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012 Jan 12;366(2):120-9. doi: 10.1056/NEJMoa1105575. Erratum in: N Engl J Med. 2016 Mar 10;374(10):998.</citation>
    <PMID>22236222</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2017</study_first_submitted>
  <study_first_submitted_qc>June 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2017</study_first_posted>
  <last_update_submitted>June 21, 2017</last_update_submitted>
  <last_update_submitted_qc>June 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Freiburg</investigator_affiliation>
    <investigator_full_name>Stéphane Cook, Prof</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <keyword>Screening</keyword>
  <keyword>Zenicor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

